#US Biosimilar Market

[kenresearch1]

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

[intentmarketresearch-imr]

Biotechnology Contract Manufacturing Market Adopts AI & Automation for Future Growth

The biotechnology contract manufacturing market is rapidly evolving, driven by increasing demand for biologics, biosimilars, and personalized medicine. In 2023, the market was valued at an impressive USD 15.8 billion, and projections indicate it will surpass USD 26.8 billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030. This robust growth highlights the sector's critical role in supporting biopharmaceutical companies with cost-efficient, scalable, and specialized manufacturing solutions.

What is Biotechnology Contract Manufacturing?

Biotechnology contract manufacturing organizations (CMOs) provide outsourced services to biotech and pharmaceutical companies. These services encompass the production of biologics, vaccines, monoclonal antibodies, and gene therapies. By leveraging CMOs, companies can focus on research and development (R&D) while ensuring efficient production processes.

Download Sample Report @ https://intentmarketresearch.com/request-sample/biotechnology-contract-manufacturing-market-3117.html  

Key Market Drivers

1. Rising Demand for Biologics and Biosimilars

Biologics and biosimilars have revolutionized treatment options for chronic diseases like cancer, diabetes, and autoimmune disorders. As demand for these products surges, biotech companies increasingly rely on CMOs to meet production needs while maintaining high quality.

2. Advancements in Gene and Cell Therapies

Gene and cell therapies have opened new avenues for treating previously untreatable conditions. These cutting-edge therapies require specialized manufacturing facilities, which CMOs are well-equipped to provide.

3. Cost Efficiency and Scalability

Building and maintaining in-house manufacturing facilities is expensive and resource-intensive. CMOs offer cost-effective solutions with scalable production capacities, enabling smaller biotech firms to compete in the market.

Market Challenges

1. Regulatory Complexity

The biotechnology sector faces stringent regulatory requirements. Ensuring compliance with global standards is a significant challenge for CMOs, requiring robust quality control systems and continuous updates to protocols.

2. Supply Chain Disruptions

Recent global events, such as the COVID-19 pandemic, highlighted vulnerabilities in the supply chain. CMOs must adapt to mitigate risks and ensure uninterrupted production.

Regional Insights

1. North America

North America dominates the biotechnology contract manufacturing market, driven by a strong biopharmaceutical industry, advanced infrastructure, and significant investment in R&D. The United States is a key contributor, with numerous biotech startups and established players relying on CMOs.

2. Europe

Europe is a significant player in the market, with countries like Germany, Switzerland, and the UK leading in biopharma innovation. The region’s regulatory framework encourages partnerships between biotech companies and CMOs.

3. Asia-Pacific

Asia-Pacific is witnessing rapid growth due to lower manufacturing costs, a skilled workforce, and increasing government support. Countries like China and India are emerging as major hubs for contract manufacturing.

Access Full Report @ https://intentmarketresearch.com/latest-reports/biotechnology-contract-manufacturing-market-3117.html 

Future Trends in Biotechnology Contract Manufacturing

1. Automation and Digitalization

The integration of automation and digital technologies in manufacturing processes is enhancing efficiency and precision. CMOs are adopting advanced analytics and AI-driven tools to streamline operations.

2. Expansion of Single-Use Technologies

Single-use technologies, such as disposable bioreactors, are gaining traction due to their cost-effectiveness and reduced risk of contamination. These technologies are reshaping production paradigms for CMOs.

3. Personalized Medicine

The shift towards personalized medicine is driving demand for smaller, more flexible manufacturing setups. CMOs are adapting to produce customized therapies at scale.

FAQs

1. What services do biotechnology CMOs provide? Biotechnology CMOs offer services such as biologics production, vaccine manufacturing, gene and cell therapy production, and regulatory compliance support.

2. Why is the biotechnology contract manufacturing market growing? The market is growing due to increased demand for biologics, advancements in gene therapies, cost efficiency, and the rise of personalized medicine.

3. Which regions dominate the biotechnology contract manufacturing market? North America leads the market, followed by Europe and the rapidly growing Asia-Pacific region.

4. What challenges do biotechnology CMOs face? Key challenges include regulatory complexities, supply chain disruptions, and the need to adopt emerging technologies.

5. What are the future trends in biotechnology contract manufacturing? Trends include automation, digitalization, the use of single-use technologies, and the growth of personalized medicine manufacturing.

About Us

Intent Market Research (IMR) is dedicated to delivering distinctive market insights, focusing on the sustainable and inclusive growth of our clients. We provide in-depth market research reports and consulting services, empowering businesses to make informed, data-driven decisions.

Our market intelligence reports are grounded in factual and relevant insights across various industries, including chemicals & materials, healthcare, food & beverage, automotive & transportation, energy & power, packaging, industrial equipment, building & construction, aerospace & defense, and semiconductor & electronics, among others.

We adopt a highly collaborative approach, partnering closely with clients to drive transformative changes that benefit all stakeholders. With a strong commitment to innovation, we aim to help businesses expand, build sustainable advantages, and create meaningful, positive impacts.

Contact Us

sales@intentmarketresearch.com

US: +1 463-583-2713

[vikibro1]

Human Insulin Drugs and Delivery Devices  Market Overview, Growth Analysis, Trends and Forecast By 2031

The Human Insulin Drugs and Delivery Devices Market sector is undergoing rapid transformation, with significant growth and innovations expected by 2029. In-depth market research offers a thorough analysis of market size, share, and emerging trends, providing essential insights into its expansion potential. The report explores market segmentation and definitions, emphasizing key components and growth drivers. Through the use of SWOT and PESTEL analyses, it evaluates the sector’s strengths, weaknesses, opportunities, and threats, while considering political, economic, social, technological, environmental, and legal influences. Expert evaluations of competitor strategies and recent developments shed light on geographical trends and forecast the market’s future direction, creating a solid framework for strategic planning and investment decisions.

Brief Overview of the Human Insulin Drugs and Delivery Devices Market:

The global Human Insulin Drugs and Delivery Devices Market is expected to experience substantial growth between 2024 and 2031. Starting from a steady growth rate in 2023, the market is anticipated to accelerate due to increasing strategic initiatives by key market players throughout the forecast period.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-insulin-drugs-and-delivery-devices-market

Which are the top companies operating in the Human Insulin Drugs and Delivery Devices Market?

The report profiles noticeable organizations working in the water purifier showcase and the triumphant methodologies received by them. It likewise reveals insights about the share held by each organization and their contribution to the market's extension. This Global Human Insulin Drugs and Delivery Devices Market report provides the information of the Top Companies in Human Insulin Drugs and Delivery Devices Market in the market their business strategy, financial situation etc.

Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Biocon (India), Boehringer Ingelheim International GmbH. (Germany), Medtronic (Ireland), Ypsomed AG (Switzerland), Julphar (UAE), Albireo Pharma, Inc. (U.S.). CeQur Simplicity (Switzerland), BD (U.S.), B. Braun SE (Germany), Novo Nordisk A/S (Denmark), WOCKHARDT (India)

Report Scope and Market Segmentation

Which are the driving factors of the Human Insulin Drugs and Delivery Devices Market?

The driving factors of the Human Insulin Drugs and Delivery Devices Market are multifaceted and crucial for its growth and development. Technological advancements play a significant role by enhancing product efficiency, reducing costs, and introducing innovative features that cater to evolving consumer demands. Rising consumer interest and demand for keyword-related products and services further fuel market expansion. Favorable economic conditions, including increased disposable incomes, enable higher consumer spending, which benefits the market. Supportive regulatory environments, with policies that provide incentives and subsidies, also encourage growth, while globalization opens new opportunities by expanding market reach and international trade.

Human Insulin Drugs and Delivery Devices Market - Competitive and Segmentation Analysis:

**Segments**

- By Product Type: Insulin Drugs (Insulin Analogs, Regular Human Insulin, Biosimilar Insulin), Insulin Delivery Devices (Insulin Syringes, Insulin Pens, Insulin Pumps) - By Indication: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes - By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies - By Geography: North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

The global human insulin drugs and delivery devices market is expected to witness significant growth from 2022 to 2029, driven by factors such as the increasing prevalence of diabetes, rising geriatric population, technological advancements in insulin delivery devices, and a growing demand for personalized medicine. The market is segmented based on product type, indication, distribution channel, and geography. With insulin drugs including insulin analogs, regular human insulin, and biosimilar insulin, and insulin delivery devices comprising insulin syringes, insulin pens, and insulin pumps, the market offers a wide array of options for healthcare providers and patients alike. By indication, the market caters to individuals with Type 1 diabetes, Type 2 diabetes, and gestational diabetes. The distribution channels for these products include hospital pharmacies, retail pharmacies, and online pharmacies, offering convenient access to insulin drugs and delivery devices for patients globally.

**Market Players**

- Novo Nordisk A/S - Sanofi - Eli Lilly and Company - Merck & Co., Inc. - Biocon - Becton Dickinson and Company - Ypsomed - Medtronic - Tandem Diabetes Care, Inc. - Insulet Corporation

The competitive landscape of the global human insulin drugs and delivery devices market includes key players such as Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Merck & Co., Inc., Biocon, Becton Dickinson and Company, Ypsomed, MedThe global human insulin drugs and delivery devices market is highly competitive, with key players vying for market share through strategies such as new product launches, partnerships, mergers, and acquisitions. Novo Nordisk A/S, a prominent player in the market, has a strong product portfolio encompassing insulin analogs and delivery devices. The company's focus on research and development has allowed it to introduce innovative solutions to meet the evolving needs of patients with diabetes. Sanofi, another major player, has a diversified portfolio of insulin products catering to different patient populations. The company's strategic collaborations and investments in emerging markets have positioned it as a key player in the global market.

Eli Lilly and Company is renowned for its commitment to diabetes care and has a range of insulin products targeting both Type 1 and Type 2 diabetes. The company's emphasis on patient education and support programs has enhanced its brand value among healthcare providers and patients. Merck & Co., Inc. has made significant strides in the insulin market with its focus on developing biosimilar insulin products. The company's strong distribution network and marketing strategies have contributed to its market presence.

Biocon, a leading biopharmaceutical company, has expanded its footprint in the human insulin market with a robust pipeline of biosimilar insulin products. The company's strategic partnerships and collaborations have bolstered its position in the competitive landscape. Becton Dickinson and Company, a key player in insulin delivery devices, offers a diverse range of products such as insulin syringes and pens. The company's focus on product innovation and quality has garnered a loyal customer base globally.

Ypsomed, a Swiss-based company specializing in insulin pumps and injection systems, has carved a niche for itself in the market with its user-friendly and technologically advanced products. The company's emphasis on patient-centric design and customization options has differentiated it from competitors. Medtronic, a global leader in medical technology, has a strong presence in the insulin pump segment. The company's continuous investment in research and**Market Players**

- Mylan N.V. (U.S.) - Teva Pharmaceutical Industries Ltd. (Israel) - Sanofi (France) - Novartis AG (Switzerland) - Bayer AG (Germany) - Lilly (U.S.) - Merck & Co., Inc. (U.S.) - AstraZeneca (U.K.) - Johnson & Johnson Private Limited (U.S.) - Biocon (India) - Boehringer Ingelheim International GmbH. (Germany) - Medtronic (Ireland) - Ypsomed AG (Switzerland) - Julphar (UAE) - Albireo Pharma, Inc. (U.S.) - CeQur Simplicity (Switzerland) - BD (U.S.) - B. Braun SE (Germany) - Novo Nordisk A/S (Denmark) - WOCKHARDT (India)

The global human insulin drugs and delivery devices market is witnessing significant growth propelled by the increasing prevalence of diabetes globally. With the rising geriatric population and technological advancements in insulin delivery devices, the market is poised for further expansion from 2022 to 2029. The market segmentation based on product type, indication, distribution channel, and geography provides a comprehensive understanding of the market landscape. The key product types in the market include insulin drugs like insulin analogs, regular human insulin, and biosimilar insulin, alongside insulin delivery devices such as insulin syringes, pens, and pumps, offering

North America, particularly the United States, will continue to exert significant influence that cannot be overlooked. Any shifts in the United States could impact the development trajectory of the Human Insulin Drugs and Delivery Devices Market. The North American market is poised for substantial growth over the forecast period. The region benefits from widespread adoption of advanced technologies and the presence of major industry players, creating abundant growth opportunities.

Similarly, Europe plays a crucial role in the global Human Insulin Drugs and Delivery Devices Market, expected to exhibit impressive growth in CAGR from 2024 to 2029.

Explore Further Details about This Research Human Insulin Drugs and Delivery Devices Market Report https://www.databridgemarketresearch.com/reports/global-human-insulin-drugs-and-delivery-devices-market

Key Benefits for Industry Participants and Stakeholders: –

Industry drivers, trends, restraints, and opportunities are covered in the study.

Neutral perspective on the Human Insulin Drugs and Delivery Devices Market scenario

Recent industry growth and new developments

Competitive landscape and strategies of key companies

The Historical, current, and estimated Human Insulin Drugs and Delivery Devices Market size in terms of value and size

In-depth, comprehensive analysis and forecasting of the Human Insulin Drugs and Delivery Devices Market

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2031) of the following regions are covered in Chapters

The countries covered in the Human Insulin Drugs and Delivery Devices Market report are U.S., Canada and Mexico in North America, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC)  in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA

Detailed TOC of Human Insulin Drugs and Delivery Devices Market Insights and Forecast to 2029

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Human Insulin Drugs and Delivery Devices Market Landscape

Part 05: Pipeline Analysis

Part 06: Human Insulin Drugs and Delivery Devices Market Sizing

Part 07: Five Forces Analysis

Part 08: Human Insulin Drugs and Delivery Devices Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Human Insulin Drugs and Delivery Devices Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Browse More Reports:

Japan: https://www.databridgemarketresearch.com/jp/reports/global-human-insulin-drugs-and-delivery-devices-market

China: https://www.databridgemarketresearch.com/zh/reports/global-human-insulin-drugs-and-delivery-devices-market

Arabic: https://www.databridgemarketresearch.com/ar/reports/global-human-insulin-drugs-and-delivery-devices-market

Portuguese: https://www.databridgemarketresearch.com/pt/reports/global-human-insulin-drugs-and-delivery-devices-market

German: https://www.databridgemarketresearch.com/de/reports/global-human-insulin-drugs-and-delivery-devices-market

French: https://www.databridgemarketresearch.com/fr/reports/global-human-insulin-drugs-and-delivery-devices-market

Spanish: https://www.databridgemarketresearch.com/es/reports/global-human-insulin-drugs-and-delivery-devices-market

Korean: https://www.databridgemarketresearch.com/ko/reports/global-human-insulin-drugs-and-delivery-devices-market

Russian: https://www.databridgemarketresearch.com/ru/reports/global-human-insulin-drugs-and-delivery-devices-market

Data Bridge Market Research:

Today's trends are a great way to predict future events!

Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 1352

Email:- corporatesales@databridgemarketresearch.com

[credenceresearchdotblog]

The Prokaryotic Recombinant Protein Market is projected to grow from USD 2725.2 million in 2024 to an estimated USD 4278.42 million by 2032, with a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032.The Prokaryotic Recombinant Protein Market has been experiencing significant growth, driven by advancements in biotechnology, expanding research in protein therapeutics, and increasing demand for cost-effective biologics production. Prokaryotic systems, particularly Escherichia coli (E. coli), have emerged as a preferred host for recombinant protein expression due to their simplicity, rapid growth, and ability to produce high yields. This article explores the key factors driving the market, challenges, applications, and future prospects.

Browse the full report at https://www.credenceresearch.com/report/prokaryotic-recombinant-protein-market

Market Drivers and Dynamics

Rising Demand for Biologics and Biosimilars Biologics, including monoclonal antibodies, vaccines, and enzymes, are critical in treating chronic diseases like cancer, diabetes, and autoimmune disorders. The production of recombinant proteins using prokaryotic systems is cost-effective and scalable, making it an attractive option for biosimilar development.

Technological Advancements in Recombinant Protein Production Continuous innovations in genetic engineering, such as CRISPR-Cas9 and synthetic biology, have improved the precision and efficiency of prokaryotic expression systems. Advanced tools for optimizing codon usage, promoters, and plasmids have significantly enhanced the expression of complex proteins.

Growing Biopharmaceutical Research and Development (R&D) The surge in R&D investments by pharmaceutical and biotech companies to develop novel therapies has fueled the demand for prokaryotic recombinant proteins. Research initiatives aimed at understanding disease pathways, drug discovery, and protein-protein interactions rely heavily on these proteins.

Applications in Diverse Sectors

Pharmaceutical and Therapeutics Prokaryotic recombinant proteins are widely used to produce therapeutic proteins such as insulin, growth hormones, and clotting factors. The affordability and scalability of prokaryotic systems make them indispensable for meeting the global demand for life-saving biologics.

Diagnostics The diagnostic industry uses recombinant proteins to develop enzyme-linked immunosorbent assays (ELISA), Western blotting, and other diagnostic tools. These proteins are essential for detecting infectious diseases, autoimmune disorders, and cancers.

Agriculture and Industrial Applications In agriculture, recombinant proteins are used to develop genetically modified crops with enhanced resistance to pests and diseases. Industrial enzymes produced in prokaryotic systems are employed in various industries, including food and beverage, textiles, and biofuels.

Challenges in the Market

Limitations in Post-Translational Modifications Prokaryotic systems lack the machinery for post-translational modifications, such as glycosylation, which are essential for the biological activity of certain therapeutic proteins. This limitation has restricted the use of prokaryotic systems for complex protein production.

Protein Misfolding and Aggregation High expression levels in prokaryotic systems can lead to misfolded or aggregated proteins, affecting their functionality. Overcoming these challenges requires optimizing culture conditions and using molecular chaperones.

Regulatory and Ethical Considerations The production of recombinant proteins must comply with stringent regulatory standards to ensure safety and efficacy. The ethical implications of genetic engineering also continue to be a topic of debate.

Future Prospects

The Prokaryotic Recombinant Protein Market is poised for continued growth, supported by advancements in synthetic biology, the integration of AI in protein design, and the development of hybrid systems that combine the strengths of prokaryotic and eukaryotic hosts. Moreover, the increasing focus on personalized medicine and precision therapies is likely to expand the market's applications.

Sustainability in protein production will also play a critical role. Efforts to reduce environmental impact, such as using renewable feedstocks and optimizing bioprocesses, will shape the market's trajectory.

Key Player Analysis:

Abnova Corporation

Batavia Biosciences

Bioclone

Cayman Chemical Company

Cusabio Technology

Eli Lilly and Company

Geltor IndieBio

Geno Technology

Kaneka and Eurogentec

Merck

Prospec Tany Technogene

Randox Laboratories

Roche

Segmentation:

By Product Type:

Hormones

Interferons

Interleukins

Others

By End-User/Application:

Biotechnology Companies

Research institutes

Contract Research organizations

Hospital

Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/prokaryotic-recombinant-protein-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[industrynewsupdates]

A Comprehensive Overview of Systemic Scleroderma Treatment Market Landscape

The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.

The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.

Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.

Gather more insights about the market drivers, restrains and growth of the Systemic Scleroderma Treatment Market

Systemic Scleroderma Treatment Market Report Highlights

• The immunosuppressors segment held the largest revenue share in 2019, followed by prostacyclin analogues

• The high preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class will support its dominant share in this space

• The U.S. held the majority of the revenue share in 2019. Expected label expansions and the expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs are expected to support market growth

• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Systemic Scleroderma Treatment Market Segmentation

Grand View Research has segmented the global systemic scleroderma treatment market based on drug class and region:

Systemic Scleroderma Treatment Drug Class Outlook (Revenue, USD Million, 2016 - 2027)

• Immunosuppressors

• Phosphodiesterase 5 inhibitors - PHA

• Endothelin Receptor Antagonists

• Prostacyclin Analogues

• Calcium Channel Blockers

• Others

Systemic Scleroderma Treatment Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

• Asia Pacific

o China

o Japan

o India

o Australia

• Latin America

o Brazil

o Argentina

o Mexico

• MEA

o South Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Systemic Scleroderma Treatment Market Intelligence Study, published by Grand View Research.

[prachicmi]

Biopharmaceuticals: Driving Innovation in Healthcare Industry

Significance in Drug Development Biopharmaceuticals, also known as biologics, are medical drugs created by living organisms through biotechnology methods instead of being chemically synthesized. They have revolutionized the treatment of various diseases over the past few decades. They are often developed to treat complex diseases like cancer, diabetes, rheumatoid arthritis that cannot be effectively treated with traditional small molecule drugs. They provide targeted treatment options with fewer side effects compared to conventional drugs.

Mechanism of Action of Biologic Drugs Biopharmaceuticals work differently than chemically synthesized small molecule drugs. Their large and complex molecular structure allows them to be highly specific and interact with the body in novel ways. Most biologics are protein-based and are produced through recombinant DNA technology, monoclonal antibodies, tissue engineering or gene therapy. They target disease pathways at the protein level using their three-dimensional molecular structure. For example, monoclonal antibody drugs bind only to specific proteins on the surface of diseased cells like cancer cells, making them an effective targeted therapy. Due to their specificity and high molecular weight, they cannot be chemically synthesized and require biotechnological manufacturing methods. Advantages over Conventional Drugs The complexity and specificity of biopharmaceuticals provide several therapeutic advantages. Firstly, they demonstrate high efficacy against diseases that were previously untreatable. Secondly, biologics elicit weaker immune responses than foreign therapeutic proteins derived from non-human sources. This allows them to be highly effective with fewer side effects. Thirdly, biologics can be engineered to have longer half-lives in the body compared to chemically synthesized drugs, reducing dosing frequency. Fourthly, they demonstrate precise targeting of cellular pathways involved in disease without impacting healthy cells. This enhances safety and tolerability. Lastly, biologics development allows for personalized medicine approaches through companion diagnostics, biomarker-guided therapies and combination treatments. Biosimilars Foster Healthcare Access and Cost Savings The development of biosimilars, which are highly similar versions of innovator biologics that have lost patent protection, has been a major driver of cost-savings in the biopharmaceutical industry. Biosimilars can be approved by regulators based on demonstrating similarity to an existing approved biological product through analytical, animal and clinical studies, without having to repeat the full clinical development process. They provide an opportunity for more affordable treatment options for patients once the high research and development costs of originator biologics have been recouped. Global biosimilars market is projected to grow at a CAGR of 28% till 2027. Companies producing biosimilars play a key role in expanding access to biologics and reducing healthcare expenditure burdens for governments and patients. Challenges in Manufacturing Despite the advantages, realization of full potential of it faces certain production and regulatory challenges. Firstly, manufacturing biologics involves complex living cellular systems making standardization and scale-up more difficult than chemicals. Secondly, quality by design approaches and stringent controls are required to ensure batch-to-batch consistency. Thirdly, characterization of complex protein structures with analytical techniques is challenging. Fourthly, the high development costs along with regulatory requirements for extensive clinical testing impacts drug pricing. Fifthly, storage and distribution of biologics requires temperature-controlled cold chain management due to susceptibility to degradation. Lastly, the possibility of immunogenicity on repeated administration and product withdrawals due to manufacturing issues pose risks. Ongoing technological innovations are helping address these challenges to some extent. Impact on Future Drug Discovery Biopharmaceuticals have expanded treatment horizons by enabling therapies against previously "undruggable" targets. Areas like gene therapy, stem cell therapy and tissue engineering hold promise for future disease modifications. The application of artificial intelligence, machine learning and digital technologies is expediting biologics development through in silico screening, protein design and manufacturing process optimization.

Get more insights on, Biopharmaceuticals

For Deeper Insights, Find the Report in the Language that You want.

Japanese Korean

About Author:

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[roshankumar7904800]

Tumor Necrosis Factor Inhibitor Drugs Market

Tumor Necrosis Factor Inhibitor Drug Market Size, Share, Trends: AbbVie Inc. Leads

Increasing Adoption of Biosimilars Driving Market Growth

Market Overview:

The Tumor Necrosis Factor (TNF) Inhibitor Drug Market is expected to develop at a CAGR of 4.5% between 2024 and 2031. The market value is predicted to rise from XX USD in 2024 to YY USD in 2031. North America currently dominates the market, owing to its high frequency of autoimmune illnesses and modern healthcare infrastructure. Key metrics include increased R&D activity, increased biologics adoption, and increased awareness of autoimmune illnesses. The market is steadily expanding due to the rising prevalence of inflammatory illnesses such as rheumatoid arthritis and psoriasis. Technological developments in drug delivery technologies as well as the introduction of biosimilars are helping to drive market growth. However, the high cost of TNF inhibitor medications and severe side effects may limit growth to some extent.

DOWNLOAD FREE SAMPLE

Market Trends:

The TNF inhibitor medicines industry is seeing a considerable shift towards the use of biosimilars. As the patents on original biologics expire, pharmaceutical companies are creating biosimilar TNF inhibitors. These biosimilars deliver equivalent efficacy at a cheaper cost, appealing to both healthcare professionals and patients. The introduction of biosimilars is increasing access to TNF inhibitor medicines, especially in emerging economies where cost has been a significant barrier. This trend is altering the competitive landscape and propelling overall market expansion by expanding patient access and treatment alternatives.

Market Segmentation:

Adalimumab, sold under a variety of brand names, has retained its position as the leading TNF inhibitor medicine in terms of market share and income. Its success is due to its wide variety of approved indications, which include rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug's efficacy, paired with its easy subcutaneous administration, has made it a popular choice among both healthcare practitioners and patients. Recent clinical trials have broadened adalimumab's possible usage. Phase III research published in the New England Journal of Medicine found it effective in treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition. This new indication has created new market potential for Adalimumab.

Market Key Players:

The TNF inhibitor drug market is highly competitive, with major players focusing on innovation and strategic collaborations. Key companies such as AbbVie Inc., Johnson & Johnson, Amgen Inc., Pfizer Inc., Novartis AG, UCB S.A., Bristol-Myers Squibb Company, Merck & Co., Inc., Biogen Inc., and Samsung Bioepis Co., Ltd. dominate the market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[lanettcdmo]

The Future of CDMOs: Key Trends Shaping the Biopharma Outsourcing Industry in 2024

In the fast-paced world of pharmaceuticals, the demand for speed, efficiency, and expertise has given rise to the prominence of Contract Manufacturing Organizations (CMOs). These organizations play a critical role in bringing innovative drugs to market while allowing pharmaceutical companies to focus on research, development, and innovation.

In this blog, we explore the evolving role of CMOs, the benefits they offer, and the latest trends shaping this dynamic industry.

What Are CMOs and Why Are They Essential?

A Contract Manufacturing Organization (CMO) is a company that provides manufacturing services to pharmaceutical and biotechnology firms. CMOs handle everything from small-scale development to large-scale commercial production. By outsourcing manufacturing to CMOs, pharmaceutical companies can save costs, enhance flexibility, and scale their operations without investing heavily in infrastructure.

Key Benefits of CMOs for Pharmaceutical Companies

Cost EfficiencySetting up and maintaining manufacturing facilities can be prohibitively expensive. CMOs offer a cost-effective solution, as pharmaceutical companies can avoid capital investment in equipment, facilities, and regulatory compliance processes.

Access to Specialized ExpertiseCMOs often possess expertise in areas like high-potency API (HPAPI) production, biologics, and sterile manufacturing that many pharmaceutical companies lack in-house.

Faster Time to MarketCMOs help accelerate production timelines, enabling quicker delivery of life-saving drugs to patients. Their established infrastructure and streamlined processes make it easier to scale production.

Regulatory CompliancePharmaceutical manufacturing requires adherence to stringent regulatory standards. CMOs invest heavily in maintaining compliance with FDA, EMA, and other global regulatory authorities, reducing the compliance burden for their clients.

Focus on Core CompetenciesBy outsourcing manufacturing, pharmaceutical companies can focus on their core strengths—such as drug discovery, R&D, and marketing—without getting bogged down by production challenges.

Emerging Trends in the Pharmaceutical CMO Industry

The pharmaceutical CMO landscape is evolving rapidly, driven by technological advancements, changing regulations, and market demands. Here are the key trends to watch:

1. Growth in Biologics Manufacturing

With the rise of biologics and biosimilars, CMOs are expanding their capabilities in areas like monoclonal antibodies, cell therapies, and gene therapies. Advanced manufacturing technologies, such as single-use bioreactors, are transforming biologics production.

2. Digital Transformation

CMOs are adopting cutting-edge technologies like Artificial Intelligence (AI), Machine Learning (ML), and Internet of Things (IoT) for process optimization, predictive maintenance, and enhanced quality control.

3. Flexible Manufacturing

The need for agile production systems is growing. CMOs are investing in modular and continuous manufacturing solutions to meet diverse client needs and improve cost-effectiveness.

4. Focus on Sustainability

Eco-friendly practices are becoming a priority, with CMOs adopting green chemistry, reducing carbon footprints, and using sustainable raw materials. This aligns with the global push toward Environmental, Social, and Governance (ESG) goals.

5. Expansion of Global Manufacturing Hubs

To ensure resilience and reduce supply chain disruptions, CMOs are setting up manufacturing facilities in emerging markets, particularly in Asia-Pacific, Eastern Europe, and Latin America.

How to Choose the Right CMO Partner

Selecting the right CMO partner is critical for a pharmaceutical company’s success. Here are some factors to consider:

Experience and Track Record: Evaluate the CMO’s experience with similar projects and their history of meeting client expectations.

Technical Expertise: Ensure the CMO has the technical capabilities to handle your product’s specific requirements.

Regulatory Compliance: Verify the CMO’s adherence to international regulatory standards.

Capacity and Scalability: Choose a partner that can scale production to meet your needs, whether for clinical trials or commercial-scale manufacturing.

Communication and Transparency: Strong communication ensures smoother collaboration and quicker resolution of issues.

Future of CMOs in the Pharmaceutical Industry

The pharmaceutical industry is evolving at an unprecedented pace, and CMOs are at the heart of this transformation. From developing advanced therapies to ensuring supply chain resilience, CMOs are becoming strategic partners rather than mere service providers. As outsourcing becomes more integral to the pharmaceutical value chain, CMOs will continue to innovate and adapt to meet the industry's demands.

Conclusion

Contract Manufacturing Organizations are not just manufacturers; they are enablers of innovation and efficiency in the pharmaceutical industry. Whether you are a pharmaceutical company seeking to optimize operations or an industry professional exploring the latest trends, understanding the role of CMOs is essential for navigating the future of healthcare.

[mordorintelligencemarketresearch]

The Albumin Industry: A Vital Component in Healthcare and Biopharmaceuticals 

Albumin, a vital protein found in blood plasma, has become an indispensable resource in the healthcare and biopharmaceutical industries. Known for its versatility and wide-ranging applications, albumin serves critical roles in medical treatments, drug delivery systems, and diagnostics. Its increasing demand across healthcare systems worldwide underscores its importance in addressing diverse clinical needs, from treating life-threatening conditions like hypovolemia and shock to enabling advanced drug formulations in biopharmaceuticals. 

The albumin market is projected to reach a value of USD 7.27 billion in 2024 and is anticipated to grow to USD 10.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.76% over the forecast period from 2024 to 2029. 

Understanding Albumin and Its Importance 

Albumin, primarily derived from human plasma, is a key protein responsible for maintaining oncotic pressure and fluid balance in the body. It also serves as a carrier for hormones, enzymes, drugs, and other vital substances. In the medical field, albumin is used to treat various conditions, including: 

Hypovolemia: Restoring blood volume in cases of severe fluid loss. 

Hypoproteinemia: Managing low protein levels due to liver or kidney diseases. 

Burns and Trauma: Providing nutritional and osmotic support during recovery. 

Neonatal Conditions: Addressing complications in premature infants. 

Beyond its therapeutic use, albumin is widely employed in research and drug formulation as a stabilizer and carrier. Its ability to bind with various molecules makes it an ideal component for drug delivery systems, especially for targeting challenging diseases like cancer and autoimmune disorders. 

Key Drivers of Growth in the Albumin Industry 

1. Rising Incidence of Chronic Diseases and Critical Conditions 

The growing prevalence of chronic diseases such as liver cirrhosis, nephrotic syndrome, and cancer has significantly increased the demand for albumin. These conditions often lead to complications requiring albumin-based therapies. Additionally, the rising number of surgeries, trauma cases, and burn injuries has further fueled the need for albumin in critical care settings. 

2. Expansion of Biopharmaceutical Applications 

Albumin is gaining prominence in the biopharmaceutical sector as a stabilizer in drug formulations and as a carrier for targeted drug delivery. With the increasing development of biologics and biosimilars, albumin's role in enhancing the stability and efficacy of therapeutic agents is driving its adoption. Technologies like albumin-fusion platforms are enabling the creation of long-acting drugs, further expanding its applications in cutting-edge treatments. 

3. Growth in Plasma Fractionation 

Advancements in plasma fractionation technology have improved the efficiency of albumin production, allowing for greater yields and quality. Plasma fractionation remains the primary method for extracting albumin from blood plasma, and innovations in this area have made albumin more accessible to meet growing demand. 

4. Increasing Awareness and Adoption in Emerging Markets 

Developing regions, particularly in Asia-Pacific and Latin America, are witnessing increased adoption of albumin due to rising awareness about its therapeutic benefits. Governments and healthcare organizations in these regions are investing in improved healthcare infrastructure, driving demand for albumin-based treatments. 

5. Regulatory Support and Strategic Partnerships 

Government initiatives and regulatory frameworks supporting plasma-derived therapies have encouraged investments in the albumin market. Furthermore, collaborations between pharmaceutical companies and research institutions are accelerating the development of novel albumin-based products, contributing to market growth. 

Challenges in the Albumin Industry 

1. Limited Plasma Supply 

Albumin production relies heavily on human plasma donations, which are subject to strict regulations and limited availability. The supply-demand gap poses a significant challenge, particularly as global demand for plasma-derived therapies continues to rise. 

2. High Production Costs 

The extraction and purification of albumin through plasma fractionation are resource-intensive processes, contributing to high production costs. These costs can limit the affordability of albumin-based therapies, particularly in low-income regions. 

3. Competition from Synthetic Alternatives 

The development of synthetic or recombinant albumin as an alternative to plasma-derived albumin is gaining traction. While these alternatives offer advantages such as reduced dependency on plasma donations, they also introduce competition that could impact the traditional albumin market. 

4. Stringent Regulatory Requirements 

Albumin production and distribution are subject to rigorous regulatory standards to ensure safety and efficacy. Navigating these regulations can be time-consuming and costly for manufacturers, delaying product approvals and market entry. 

5. Ethical and Supply Chain Concerns 

The ethical considerations surrounding plasma donation, coupled with complex supply chain logistics, present additional challenges. Ensuring a sustainable and ethical plasma supply chain is critical for the long-term growth of the albumin industry. 

Emerging Trends Shaping the Albumin Industry 

1. Recombinant Albumin Development 

Recombinant albumin, produced through genetic engineering, is gaining attention as a sustainable alternative to plasma-derived albumin. It offers advantages such as consistent quality, reduced risk of contamination, and scalability in production. 

2. Integration with Advanced Drug Delivery Systems 

Albumin is increasingly being integrated with nanoparticle-based drug delivery systems to enhance targeted drug delivery. This innovation is particularly relevant in oncology, where albumin-bound drugs like paclitaxel (marketed as Abraxane) have demonstrated improved efficacy and reduced side effects. 

3. Expansion of Albumin in Diagnostics 

In addition to its therapeutic applications, albumin is being explored for use in diagnostic tools, such as in vitro assays and biomarkers for detecting diseases. Its role in diagnostics is expected to expand as research uncovers new applications. 

4. Sustainability and Ethical Plasma Sourcing 

The industry is focusing on creating more sustainable plasma collection practices and ensuring ethical sourcing to meet growing demand. Initiatives to increase plasma donation awareness and streamline collection processes are gaining momentum. 

5. Personalized Medicine and Albumin Fusion Technology 

Albumin fusion technology is enabling the development of personalized therapies by extending the half-life of drugs and optimizing their pharmacokinetics. This trend aligns with the broader movement toward personalized medicine, offering tailored treatment options for patients. 

Conclusion 

The albumin industry is an essential pillar of modern healthcare, addressing critical medical needs while supporting advancements in biopharmaceuticals and diagnostics. As demand for albumin continues to grow, driven by rising chronic disease prevalence, expanding biopharmaceutical applications, and technological innovations, the industry is poised for sustained growth. 

While challenges such as plasma supply limitations and high production costs persist, emerging trends like recombinant albumin and advanced drug delivery systems offer promising solutions. With a focus on sustainability, innovation, and accessibility, the albumin industry is set to play a transformative role in shaping the future of healthcare, ensuring better outcomes for patients worldwide.    For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/albumin-market 

[kenresearch1]

The US Biosimilar market is expected to reach ~USD 96 Bn Industry by 2028

Buy Now

The United States Biosimilar market which currently has a market size of ~USD 9.48 Bn. is expected to grow at a CAGR of ~40% in the next five years and become a ~USD 96 Bn. industry as per the findings of Ken Research.

STORY OUTLINE

Biosimilar drugs tend to be cost effective and this reason is a major factor which contributes highly to the growth of US Biosimilar market.

Rising geriatric population results in an increased demand for Biosimilar drugs which ultimately helps in the growth of US Biosimilar market.

Increasing cases of chronic diseases in the country also raises the demand for Biosimilar drugs thereby accelerating the US Biosimilar market.

Growing partnerships between companies to develop Biosimilar drugs also helps in the growth and expansion of the US Biosimilar market.

A fast growing industry, cost effective nature of Biosimilar, rising cases of chronic diseases, and increase in geriatric population, along with rising strategic partnerships are the various reasons responsible for the growth of US Biosimilar market. This market is anticipated to grow at a CAGR of ~40% in the next five years.

Click to read more about US Biosimilar Market

1.Cost effective nature of Biosimilar drugs: major factor responsible for the growth of US biosimilar market

One of the major reasons behind the significant growth of US Biosimilar market is the cost-effective nature of Biosimilar drugs.

Typically, Biosimilar drugs cost lesser than the generics products due to which they have gained popularity in the healthcare sector. Generally, these drugs cost 30% lesser than the generic or original drugs.

Lucentis is an original drug which is primarily used to treat macular degeneration. This drug is priced at around USD 1200 in the United States.

 Its most common biosimilar is Cimerli which is priced way lesser than Lucentis. It costs around USD 800 in the United States.

Humira is another generic biological which is generally used in the treatment of various autoimmune diseases. This drug is priced at approximately USD 3000. Amjevita is its popular Biosimilar drug which is priced at about USD 1500 in the US which is approximately 50% cheaper than the original drug.

Rituxan is a generic drug which is typically used to treat blood cancer. It is priced at about USD 1000 in the US. Its popular biosimilar drug is Truxima which is priced at about USD 900 in the US.

Herceptin is another expensive generic drug which is mainly used in the treatment of various cancers primarily stomach and breast cancers. The average cost of this generic drug in the US is USD 6800. Ogiviri is its biosimilar drug which is sold at approximately USD 3900 in the US.

Thus, it is evident that biosimilar drugs tend to be more cost effective than the original or generic drugs. Their cost effective nature is a major contributor of the growth of US Biosimilar market.

2.Rising geriatric population: generating the demand for Biosimilar drugs

Click here:- To Download a Sample Report

The geriatric population also has been increasing at a significant rate in the United States. The main reasons behind geriatric population are increase in life expectancy rates and decrease in fertility rates.

There were almost 25 aged people per 100 people in the US in 1980s. The number rose to 32 aged people per 100 people in 1990s. In 2000s, there were 35 aged people per 100 people. 2010 witnessed 40 aged people per 100 people.

 In 2020s, the number reached to 54 aged people per 100 people. This number is further expected to reach 72 aged people per 100 people in 2030s.

As the population rises, aged population becomes vulnerable to many health conditions and they end up requiring many medicines for the treatment of their health conditions.

In the US, approximately 80% of aged people (above 65) have at least one chronic health condition.

The rise in aged population also results in an increased demand for Biosimilar drugs as most of the aged population do not have any strong source of income and thus, they cannot afford generic drugs or original drugs which tend to be really expensive.

Thus, the geriatric population also contribute to the growth of the US Biosimilar market.

3.Increasing cases of chronic diseases: accelerating the US Biosimilar market

The prevalence of chronic health conditions is very high in the United States. A chronic disease is a health condition that prevails for a longer period. Some of the major chronic diseases in the US are cardiovascular diseases, cancer, diabetes, kidney diseases, Alzheimer’s, etc.

In the 2010, there were almost 140 million people living with chronic diseases. In 2015, USA witnessed approximately 150 million people with chronic diseases. This number rose to 155 million people in 2020. Further, this number is anticipated to become 165 million and 170 million people in 2025 and 2030 respectively.

As the prevalence of chronic health conditions rises, their dependence of medicines and drugs also rises. However, not everyone is able to afford original or generic drugs because they tend to be expensive. Thus, that is where the need to develop biosimilar rises.

Moreover, any country would not like to see its people suffer because they cannot afford original drugs. Thus, the countries put emphasis on developing cost effective drugs in the form of Biosimilar drugs.

4.Increasing partnerships between pharmaceutical companies to develop Biosimilar drugs:

Click here:- To Request for Custom Report

Biocon Biologics, a US firm, was involved in the acquisition of Viatris which is a global organization and is concerned with making Biosimilar drugs in the fields of endocrinology, and oncology along with immunology. The main aim of this acquisition was to make their portfolio as well as future Biosimilar drugs pipeline strong.

AbbVie collaborated with Samsung as well as Amgen to develop Biosimilar drugs for Humira which is a generic drug. For this purpose, AbbVie has started to give the license to Samsung as well as Amgen in various countries to produce the Biosimilar.

Teva Pharmaceuticals, which is a pharmaceutical company concerned with development of generic drugs formed a strategic partnership with Alvotech, which is Biosimilar pharmaceutical company to strengthen their business for developing Biosimilar drugs.

Sandoz and Just – Evotech Biologics decided to collaborate through a partnership to develop various Biosimilar drugs. This partnership also as resulted into former’s pipeline’s expansion to more than 20 biosimilar drugs.

Merck Bioventures and Hanwha made a partnership which involved approximately USD 7 Tn. to make a Biosimilar version of Enbrel which is a generic drug primarily used to treat Rheumatoid Arthritis and is currently developed by Pfizer and Amgen.

CONCLUSION

The United States Biosimilar Market can be best described as a market that is associated with the development of Biosimilar drugs which are an exact copy of original or generic drugs. There are various factors responsible for the growth of US Biosimilar Market.

Some of the major factors contributing to the growth of this market includes the cost-effective nature of Biosimilar drugs, rising geriatric population, rising cases of chronic diseases and increasing partnerships between companies to develop Biosimilar drugs.

[healthcarediagnosticmarket]

Injectable Drug Delivery Market Key Player Analysis: Growth Insights and Forecasts , Business Strategies, Challenges and Future Demand 2033

Injectable Drug Delivery Market Poised to Reach USD 1,982.0 Billion by 2032 | Straits Research

Market OverviewThe global injectable drug delivery market was valued at USD 682.1 billion in 2023 and is expected to grow at a CAGR of 12.4% over the forecast period (2024–2032), reaching USD 1,982.0 billion by 2032. This rapid growth is driven by increasing demand for advanced drug delivery systems, enhanced patient compliance, and rising prevalence of chronic diseases.

Market DefinitionInjectable drug delivery refers to administering drugs directly into the body via injection, ensuring rapid absorption and enhanced bioavailability. This includes devices such as syringes, auto-injectors, and wearable injectors, catering to various end-user sectors like hospitals, home care settings, and clinics.

Latest Market Trends

Advancements in Wearable Injectors: Rising adoption of wearable injectors for continuous and accurate drug delivery.

Development of Smart Auto-Injectors: Integration of IoT and AI for enhanced drug administration and patient monitoring.

Focus on Sustainability: Key players prioritizing eco-friendly and recyclable materials for injectables.

Get a Full PDF Sample Copy of the Report

Key Growth Factors

Rising prevalence of chronic diseases like diabetes and cancer.

Growing demand for self-administered drug delivery systems.

Technological advancements in injectable devices.

Key Market Opportunities

Expansion in emerging economies across Asia-Pacific.

Development of biologics and biosimilars driving demand for injectables.

Increasing investment in R&D for innovative drug delivery solutions.

Market Segmentation

By Device Type

Conventional Injectable

Pre-filled Syringes

Auto-injectors

Pen-injectors

Wearable

By Application

Freeze-dried Products

Injectable Sterile Products

By End-User

Hospitals

Home Care Settings

Clinics

Access Detailed Segmentation

Key Players

BD (New Jersey, U.S)

SHL Medical AG (Switzerland, Europe)

Schott AG (Germany, Europe)

West Pharmaceutical Services, Inc. (Pennsylvania, U.S)

Pfizer Inc. (New York, U.S)

Insulet Corporation (Massachusetts, U.S)

Elcam Medical (Israel, Middle East)

Eli Lilly and Company (Indiana, U.S)

Ypsomed AG (Switzerland, Europe)

Gerresheimer AG (Germany, Europe)

Baxter International Inc (Illinois, U.S)

Regional Insights

Dominated Region: North America leads the market due to technological advancements and high healthcare expenditure.

Fastest Growing Region: Asia-Pacific is projected to witness the highest growth due to increasing healthcare investments and a large patient population.

For More Information or Query or Customization Before Buying, Visit

This draft exceeds 700+ words when expanded and can be tailored further with additional specifics. Let me know if you'd like any refinements or additional insights!

About Straits Research

Straits Research is dedicated to providing businesses with the highest quality market research services. With a team of experienced researchers and analysts, we strive to deliver insightful and actionable data that helps our clients make informed decisions about their industry and market. Our customized approach allows us to tailor our research to each client's specific needs and goals, ensuring that they receive the most relevant and valuable insights.

Contact Us

Email: sales@straitsresearch.com 

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: +1 6464807505, +44 203 318 2846

[parkavifinance]

Market Update

Expect a Weak Opening for Our Market Today | ​⁠@ParkaviFinance http://youtube.com/post/UgkxDoNBqLcyC9dkUSZDBwJ5oLQx0IgfhOTL?si=G5d2RjzuIroK5XjP

The benchmark indices managed to end higher for the 4th consecutive week. Friday’s second-half recovery helped Nifty 50 close 220 points higher, supported by FMCG, Infra, Financial services (private banks), IT, and Auto stocks. However, the broader market underperformed throughout the week. FIIs net bought ₹2,335.3 crore, while DIIs net sold ₹732.2 crore in the cash market on Friday. Primary market activity is set to significantly pick up with 6 mainboard IPOs opening for subscription later this week, and 5 companies making their debut on the exchanges.

**US Market Update:**

- Dow closed 0.2% lower

- Nasdaq closed 0.1% higher

- S&P ended flat

Crude oil prices are currently hovering at $74+ per barrel on expectations of sanctions on Russia and Iran. The market is now focusing on the outcome of the US FED meeting due on Wednesday, with high optimism for a 25 bps rate cut. Asian markets are trading lower, and a weak start for our market is expected due to subdued global cues.

### Key Actionable Insights:

**1. Jubilant Foodworks**: Initiated voluntary liquidation proceedings for Hashtag Loyalty Pvt., investment valued at ₹25 crore - **Neutral in short term** 

**2. Godavari Biorefineries**: Announces capacity addition of 200 KLPD corn/grain-based distillery - **Positive in long term** 

**3. Dixon Technologies**: Signed a binding term sheet with Vivo India for OEM business - **Positive in long term** 

**4. ONGC**: No concrete plans yet for listing ONGC Green - **Neutral in short term** 

**5. GE Power**: Received ₹18.3 crore purchase order extension for boiler parts supply - **Positive in long term** 

**6. Biocon**: CHMP issued a positive opinion for YESINTEK, an Ustekinumab biosimilar - **Positive in long term** 

**7. Waaree Energies**: Investing ₹5.5 crore to acquire 55 lakh shares in Ewaa Renewable Techno Solutions - **Positive in long term** 

**8. Afcons Infra**: Won ₹1,007 crore EPC order from Madhya Pradesh Metro Rail Company - **Positive in short to medium term** 

**9. Samvardhan Motherson**: Acquiring Brazil-based Baldi Industria E Comercio for $7.8 million - **Positive in long term** 

**10. IRB Infrastructure**: Approved implementation of Ganga Expressway Project - **Positive in long term** 

**11. Happy Forgings**: Secured ₹140 crore order to supply crankshafts for domestic passenger vehicles segment - **Positive in long term** 

**12. One 97 Communications**: Completed the sale of stock acquisition rights in Japan-based Paypay Corp - **Positive in short term** 

**13. KSB**: Launched a reciprocating pump in the plunger pump category - **Neutral to Positive in short term** 

**14. Genus Power Infrastructure**: Commenced commercial production at a new manufacturing facility in Assam - **Positive in long term** 

**15. Lemon Tree Hotels**: Signed a licence agreement for a 74-room hotel in Gujarat - **Positive in long term** 

**16. HG Infra Engineering**: Received an order worth ₹862 crore from NHAI - **Positive in long term** 

**17. Lupin**: Acquired anti-diabetes trademarks from Boehringer Ingelheim International GmbH - **Positive in long term** 

**18. JK Paper**: Approved acquisition of a majority stake in Radhesham Wellpack - **Positive in medium to long term** 

**19. Globus Spirits**: Launched new brands in Uttar Pradesh - **Positive in long term** 

**20. JSW Energy**: Maharashtra State Electricity Discom Co. filed a petition before MERC - **Neutral to marginally Negative in short term** 

**21. Bharat Forge**: Approved additional investment in Kalyani Powertrain - **Positive in long term** 

**22. Mazagon Dock Shipbuilders**: Clarified no delay communication received for Project P751 - **Neutral in short term** 

**23. Reliance Industries**: Acquired a 74% stake in Navi Mumbai IIA for ₹1,628 crore - **Positive in long term** 

**24. Premier Explosives**: Entered MoU with Global Munition for a joint venture - **Positive in long term** 

**25. Aurobindo Pharma**: Positive opinion for Zefylti biosimilar - **Positive in long term** 

**26. Nazara Technologies**: Nodwin acquired 100% stake in Trinity Gaming India - **Neutral to Positive in short term** 

**27. Elcid Investments**: Submitted NBFC registration application with RBI - **Neutral to Positive in short term**

### IPO Offerings:

- **Inventurus Knowledge Solutions**: Subscribed 2.65 times on day 2.

- **International Gemmological Institute (India)**: Subscribed 0.17 times on day 2.

### Insider Trades:

- **Godrej Properties**: Promoter Godrej Seeds and Genetics bought 55,000 shares.

- **MTAR Technologies**: Promoter sold 7.9 lakh shares.

### Pledge Share Details:

- **Lloyds Metals and Energy**: Revised pledge for 51.54 lakh shares.

### Trading Tweaks:

- **Ex/record bonus Issue**: Sky Gold (9:1).

- **Ex/record stock split**: PC Jeweller.

- **Moved in short-term ASM**: Zinka Logistics Solutions.

- **Moved out short-term ASM**: Avalon Technologies, HEG, Niva Bupa Health Insurance Co.

### Management Meetings:

- **Globus Spirits**: Meeting investors and analysts on Dec. 18.

- **Five Star Business Finance**: Meeting investors and analysts on Dec. 17.

- **Shriram Finance**: Meeting investors and analysts on Dec. 18.

- **Godawari Power and Ispat**: Meeting investors and analysts on Dec. 18.

- **Varroc Engineering**: Meeting investors and analysts on Dec. 19.

- **Ceigall India**: Meeting investors and analysts on Dec. 18.

### Fund Flows – Cash Market:

- **FII (₹ crore)**: +2,335.3

- **DII (₹ crore)**: -732.2

### Bulk Deals – BSE:

- **PANORAMA STUDIOS LEADING LIGHT FUND VCC**: Bought 5,00,000 shares (0.7%) at ₹230.0 each.

---

:

"Stay updated with the latest market insights, stock analysis, and key actionable news. Expect a weak opening for the market today with detailed updates on Nifty, Bank Nifty, IPO offerings, insider trades, and more."

- #MarketAnalysis

- #StockMarketUpdates

- #NiftyLevels

- #BankNiftyLevels

- #IPOUpdates

- #TradingInsights

- #FinancialNews

- #InsiderTrades

:

- Market opening

- Stock market analysis

- Nifty and Bank Nifty levels

- IPO allotments

- Financial market news

- Trading updates

### Call-to-Action (CTA):

"🔔 Don't forget to subscribe and hit the notification bell for more market insights and trading updates! Share your thoughts and questions in the comments below."

[willyskristina]

Erythropoietin Stimulating Agents Market

Erythropoietin Stimulating Agents Market Size, Share, Trends: Amgen Inc. Leads

Shift Towards Biosimilar Erythropoietins Gains Momentum

Market Overview:

The global erythropoietin stimulating agents market is projected to grow significantly, driven by rising prevalence of chronic kidney disease and cancer, increasing adoption of biosimilars, and advancements in drug delivery technologies. North America stands out as the dominant region, accounting for a substantial share of the global market. The market for erythropoietin stimulating drugs is steadily expanding due to an ageing population, an increase in the frequency of anemia in chronic diseases, and expanding oncological applications.

The industry is also benefiting from the development of long-acting ESAs and the launch of new formulations, which lead to better patient compliance and treatment outcomes. 

DOWNLOAD FREE SAMPLE

Market Trends:

The erythropoietin stimulating agents market is shifting significantly towards biosimilar pharmaceuticals, indicating the growing need for cost-effective treatment choices and greater healthcare cost reduction initiatives. This tendency is encouraging competition and innovation in ESA development, with firms focusing on generating high-quality biosimilars that are as effective as reference drugs but at a cheaper cost. For example, the release of biosimilar epoetin alfa has gained popularity, with up to 30% cost reductions over the original medicine. Sales of biosimilar ESAs have climbed significantly year on year, demonstrating high market acceptability and penetration, especially in Europe and emerging regions.

Market Segmentation:

Epoetin Alfa dominates the market, accounting for a significant share of global sales in 2023. The Epoetin Alfa sector continues to dominate the erythropoietin stimulating agents market, owing to its well-established effectiveness profile, broad range of approved uses, and availability of biosimilar variants. Epoetin alfa, including originator and biosimilar medicines, is still the most commonly given ESA worldwide, notably for the treatment of anemia caused by chronic renal disease. Sales of epoetin alfa products have shown a consistent growth trend.

Epoetin alfa is especially common in the dialysis setting, where it has long been used to treat anemia. Recent industry figures show that a large percentage of dialysis patients globally are given epoetin alfa as their primary ESA. This tendency is backed by the drug's favorable pharmacokinetic profile, which allows for varied dosing regimens, as well as the considerable clinical expertise gained from years of use. Furthermore, the development of biosimilar epoetin alfa medicines has greatly increased market access, particularly in cost-conscious healthcare systems. The availability of these less expensive alternatives has resulted in a significant increase in epoetin alfa prescriptions in emerging nations over the last two years.

Market Key Players:

Prominent players in the erythropoietin stimulating agents market include Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson (Janssen), Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Hospira Inc. (now part of Pfizer), Biocon Limited, LG Life Sciences Ltd., Intas Pharmaceuticals Ltd., Celltrion, Inc., Emcure Pharmaceuticals Ltd., and Dong-A ST Co., Ltd. These companies are leading the market with their innovative approaches, extensive product portfolios, and robust distribution networks, continuously setting industry standards and driving market growth.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[kristinahertzz]

Microscopic Polyangiitis Treatment Market

Microscopic Polyangiitis Treatment Market Size, Share, Trends: GlaxoSmithKline plc Leads

Biologics Emerge as Promising Treatment Options Offering Targeted Therapy and Improved Outcomes

Market Overview:

The Microscopic Polyangiitis Treatment Market is witnessing significant growth driven by the rising prevalence of the disease and advancements in treatment options. North America stands out as the fastest-growing region, owing to its advanced healthcare infrastructure and high awareness levels among healthcare professionals. The market encompasses various treatment modalities, including immunosuppressants, biologics, and combination therapies, all aimed at managing this rare autoimmune disease effectively.

The increasing incidence of microscopic polyangiitis and the growing awareness among healthcare providers are key drivers propelling the market forward. Improved diagnostic techniques have led to earlier detection, further fueling the demand for effective treatment options. Additionally, government initiatives and research funding for rare diseases contribute to market expansion, highlighting the importance of innovation in therapeutic approaches. 

DOWNLOAD FREE SAMPLE

Market Trends:

Biologics are emerging as promising treatment options for microscopic polyangiitis, offering targeted therapy and improved outcomes. Recent clinical trials show biologics can induce remission in up to 75% of patients within six months, surpassing traditional therapies. This trend is driven by the precision and efficacy of biologics in targeting specific immune system components involved in the disease.

Market Segmentation:

Immunosuppressants dominate the microscopic polyangiitis treatment market, accounting for the largest market share. These drugs play a crucial role in managing the autoimmune aspects of the disease, offering effective solutions for inducing remission and preventing relapse. Cyclophosphamide and rituximab are prominent immunosuppressants, with recent clinical trials demonstrating their superior efficacy. For instance, rituximab-based regimens achieved complete remission in up to 80% of patients within six months, outperforming traditional therapies. The segment's growth is further fueled by the increasing adoption of combination therapies, which enhance treatment efficacy and reduce the risk of relapse.

In addition to their effectiveness, the introduction of biosimilars has increased the accessibility of immunosuppressants, especially in emerging markets. Biosimilars have led to a 30% reduction in treatment costs, making these therapies more affordable for a broader patient population. This trend is expected to continue, solidifying immunosuppressants' position as the cornerstone of microscopic polyangiitis treatment.

Market Key Players:

Prominent players in the microscopic polyangiitis treatment market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Genentech, Inc., ChemoCentryx, Inc., Novartis AG, and Bristol-Myers Squibb Company. These companies are at the forefront of innovation, continuously investing in research and development to bring advanced therapies to market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/